Travis Steed
Stock Analyst at Barclays
(2.76)
# 1,833
Out of 4,869 analysts
85
Total ratings
42.65%
Success rate
6.72%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $168.42 | +54.97% | 8 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $256.87 | +24.58% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $132.99 | +12.79% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $73.57 | +15.54% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $73.83 | +21.90% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $17.91 | +78.67% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $29.99 | +50.05% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $18.98 | +137.09% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $375.56 | -16.13% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $303.15 | -2.69% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $9.73 | +64.44% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $20.22 | +63.20% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $91.22 | +75.40% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $509.36 | -38.16% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $2.62 | +205.34% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $9.77 | +155.89% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $13.28 | +540.06% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $80.00 | +56.25% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $86.34 | +67.94% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $101.30 | -49.65% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $52.19 | +235.31% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $11.60 | +365.52% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $79.19 | -72.22% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $168.42
Upside: +54.97%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $256.87
Upside: +24.58%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $132.99
Upside: +12.79%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $73.57
Upside: +15.54%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $73.83
Upside: +21.90%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $17.91
Upside: +78.67%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $29.99
Upside: +50.05%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $18.98
Upside: +137.09%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $375.56
Upside: -16.13%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $303.15
Upside: -2.69%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $9.73
Upside: +64.44%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $20.22
Upside: +63.20%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $91.22
Upside: +75.40%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $509.36
Upside: -38.16%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $2.62
Upside: +205.34%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $9.77
Upside: +155.89%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $13.28
Upside: +540.06%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $80.00
Upside: +56.25%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $86.34
Upside: +67.94%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $101.30
Upside: -49.65%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $52.19
Upside: +235.31%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $11.60
Upside: +365.52%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $79.19
Upside: -72.22%